ReviewKidney international supplements2018
Novel therapies for diabetic kidney disease.
Review in Kidney international supplements, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies.Journal of clinical medicine · 2026Review
- Attending an integrated nephrology and diabetology outpatient service can improve diabetic kidney disease treatment: a single-center experience.Acta diabetologica · 2025Article
- The therapeutic effect of mesenchymal stem cells in diabetic kidney disease.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- LncRNA as a regulator in the development of diabetic complications.Frontiers in endocrinology · 2024Review
- Nephroprotective Properties of Antidiabetic Drugs.Journal of clinical medicine · 2023Review
- Chronic Kidney Disease Management in the Middle East and Africa: Concerns, Challenges, and Novel Approaches.International journal of nephrology and renovascular disease · 2023Review
- Molecular programs associated with glomerular hyperfiltration in early diabetic kidney disease.Kidney international · 2022Article
- Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis.EClinicalMedicine · 2022Article
- Deciphering the Efficacy and Mechanisms of Chinese Herbal Medicine for Diabetic Kidney Disease by Integrating Web-Based Biochemical Databases and Real-World Clinical Data: Retrospective Cohort Study.JMIR medical informatics · 2021Article
- Cardiorenal Protection in Diabetic Kidney Disease.Endocrinology and metabolism (Seoul, Korea) · 2021Review
- Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes.Therapeutic advances in endocrinology and metabolism · 2021Review
- The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.Endocrine reviews · 2020Review
- Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Review
- Review
- Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.International journal of molecular sciences · 2019Review
- Economic Burden of ESRD to the Malaysian Health Care System.Kidney international reports · 2019Article
- Inflammatory proteins in diabetic kidney disease-potential as biomarkers and therapeutic targets.Annals of translational medicine · 2019Article
- Comment on: Metabolic surgery improves renal injury independent of weight loss: a meta-analysis.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 30 years there have been many complementary therapies developed to achieve glycemic control and have an impact on cardiovascular outcomes, as well as reduce the risk of microvascular disease. The 2 most notable new entries have been the sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide-1 (GLP-1) agonists. Both these classes of agents have demonstrated reductions in cardiovascular event rates as well as reductions in blood pressure and weight. Moreover, while both have demonstrated a benefit in slowing nephropathy progression, the SGLT2 inhibitors appear to have a significantly greater effect compared with the GLP-1 agents. There is an ongoing trial specifically powered for renal disease progression, CREDENCE (Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy). Additionally, there are 2 other classes of agents being tested to slow nephropathy progression, a selective endothelin-1 receptor antagonist, atrasantan, in the SONAR (Study of Diabetic Nephropathy With Atrasentan) trial and a nonsteroidal mineralocorticoid receptor antagonist, finerenone, in the FIDELIO (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus) trial. These and other studies are discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.